Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Psychomotor effects of mexazolam vs placebo in healthy volunteers
Publication

Publications

Psychomotor effects of mexazolam vs placebo in healthy volunteers

Title
Psychomotor effects of mexazolam vs placebo in healthy volunteers
Type
Article in International Scientific Journal
Year
2002
Authors
Silveira, P
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Vaz Da Silva, M
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Dolgner, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Almeida, L
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 22
Pages: 677-684
ISSN: 1173-2563
Publisher: Springer Nature
Other information
Authenticus ID: P-000-QZB
Abstract (EN): Objective: Mexazolam is an oxazolo-benzodiazepine demonstrating chemical similarities to oxazolam and cloxazolam. This trial aimed to assess the effect of mexazolam on psychomotor performance. Design: The study was a double-blind, single-dose, randomised, two-way crossover, placebo-controlled trial. Study participants: 33 healthy male and female adult volunteers. Main outcome measures: Psychomotor performance was evaluated through the Leeds Psychomotor Test Battery [critical flicker fusion (CFF) threshold and choice reaction time with its three components (recognition reaction time - RRT, motor reaction time - MRT, and total reaction time - TRT)] and, in an exploratory way, a car-driving simulation (CDS). After performing a baseline test set, each volunteer received, in a randomised fashion, either a single oral dose of mexazolam 1 mg or placebo and, 3 hours later, the test set was repeated. After a washout of at least 10 days, the procedures were repeated in a crossover way. Tolerability was assessed through the reporting of adverse events. Results: A total of 33 healthy subjects were enrolled. In the Leeds Psychomotor Test Battery, no statistically significant differences were found between post-versus pre-placebo results, post-versus pre-mexazolam results, and placebo versus mexazolam results (post-administration: CFF: p = 0.480, RRT: p = 0.195, MRT: p = 0.470, TRT: p = 0.169). In the CDS, there were no statistical differences between placebo and mexazolam scores [pre-administration: total time score (TTS): p = 0,519, best lap time (BLT): p = 0.499; post-administration: TTS: p = 0.940. RRT: p = 0.995]. There was a statistically significant improvement between post- and pre-placebo scores (TTS: p = 0.032, BLT: p = 0.023) and between post- and pre-mexazolam scores (TTS: p = 0.016, BLT: p = 0.030), indicating a learning effect induced by the repetition of the tests. A total of three volunteers reported a total of three adverse events: somnolence, which occurred following mexazolam administration, and headache and flu-like syndrome, which occurred after placebo administration. Conclusions: Mexazolam does not have psychomotor performance-impairing effects at therapeutic doses. Reduced effects on psychomotor performance in anxious patients may lead to better compliance and to specific indications for this benzodiazepine.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 8
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Relative bioavailability of two enteric-coated formulations of omeprazole following repeated doses in healthy volunteers (2001)
Article in International Scientific Journal
Vaz Da Silva, M; Hainzl, D; Almeida, L; Dolgner, A; Silveira, P; Maia, J; soares-da-silva, p

Of the same journal

Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic Dermatitis (2024)
Another Publication in an International Scientific Journal
Freitas, E; Paiva Lopes, MJ; Cruz, MJ; Sousa, D; Valente, AC; Duarte, B; Teixeira, L; Rosas, G; Caetano, M; Mota, A; Filipe, P; Torres, T
Relative bioavailability of two enteric-coated formulations of omeprazole following repeated doses in healthy volunteers (2001)
Article in International Scientific Journal
Vaz Da Silva, M; Hainzl, D; Almeida, L; Dolgner, A; Silveira, P; Maia, J; soares-da-silva, p
One year of lamivudine therapy for Portuguese patients with chronic hepatitis B (2003)
Article in International Scientific Journal
Areias, J; Calinas, F; Porto, A; Carvalho, A; Freitas, D; Macedo G; Noronha, R; Cotter, J; Melico Silvestre, A; Peixe, R; Pratas, J; Barrote, D; Teixeira, R; Augusto, F; Carrilho, I; Campante, F; Velosa, J; Carvalho, L; Duarte, MA; Guerreiro, H...(mais 23 authors)
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends (2022)
Article in International Scientific Journal
Figueiredo, A; Costa, L; Maurício, MJ; Figueira, L; Ramos, R; Carlos Silva
Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder (2001)
Article in International Scientific Journal
Vaz-Serra, A; Figueira, ML; Bessa-Peixoto, A; Firmino, H; Albuquerque, R; Paz, C; Dolgner, A; Vaz Da Silva, M; Almeida, L

See all (9)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-16 at 07:38:21 | Privacy Policy | Personal Data Protection Policy | Whistleblowing